Zakaria Achercouk

Zakaria Achercouk

Auto-generated profile, based on publicly available information

Zakaria Achercouk

University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
IFIbrahim T. Fazmin
Ibrahim T. Fazmin
ZAZakaria Achercouk
Zakaria Achercouk
CECharlotte Edling
Charlotte Edling
Asri SaidAsri Said
Asri Said
KJKamalan Jeevaratnam
Kamalan Jeevaratnam
Coronary artery disease (CAD) is the leading cause of sudden cardiac death in adults, and new methods of predicting disease and risk-stratifying patients will help guide intervention in order to reduce this burden. Current CAD detection involves multiple modalities, but the consideration of other biomarkers will help improve reliability. The aim of this narrative review is to help researchers and clinicians appreciate the growing relevance of miRNA in CAD and its potential as a biomarker, and also to suggest useful miRNA that may be targets for future study. We sourced information from several databases, namely PubMed, Scopus, and Google Scholar, when collating evidentiary information. MicroRNAs (miRNA) are short, noncoding RNAs that are relevant in cardiovascular physiology and pathophysiology, playing roles in cardiac hypertrophy, maintenance of vascular tone, and responses to vascular injury. CAD is associated with changes in miRNA expression profiles, and so are its risk factors, such as abnormal lipid metabolism and inflammation. Thus, they may potentially be biomarkers of CAD. Nevertheless, there are limitations in using miRNA. These include cost and the presence of several confounding factors that may affect miRNA profiles. Furthermore, there is difficulty in the normalisation of miRNA values between published studies, due to pre-analytical variations in samples.

30 July 2024 in Archives of Disease in Childhood
Verified
Journal Article
Open access
PDF file
SGSwapnil G. Ghotane
Swapnil G. Ghotane
RHRaeena Hirve
Raeena Hirve
JFJulia Forman
Julia Forman
DTDaniel Tan
Daniel Tan
ZAZak Achercouk
Zak Achercouk
IWIngrid Wolfe
Ingrid Wolfe
Context There is a dearth of high-quality evidence on integrated, coordinated and cost-effective care for children with special health and care needs (CSHCN). Objective To assess the effectiveness of integrated/coordinated care models for CSHCN. Data sources Embase, Ovid Medline(R), HMIC Health Management Information Consortium, Maternity & Infant Care Database (MIDIRS), PsycARTICLES, PsycINFO, Social Policy and Practice, Cochrane Central Register of Controlled Trials (CENTRAL), Global Health and PubMed. Study selection Inclusion criteria comprised (1) randomised trials, including cluster randomised trials; (2) an integrated/coordinated care intervention; (3) for children and young people under 25 with special healthcare needs including medical complexity; (4) assessing child-centred outcomes, health-related quality of life among parents and carers, and health or social care use, processes of care and satisfaction with care. Data extraction Data were extracted and assessed by two researchers, and descriptive data were synthesised according to outcome and intervention. Results 14 randomised controlled studies were included. Seven out of the 14 studies had a dedicated key worker/care coordinator as a vital part of the integrated/coordinated care intervention; however, the certainty of evidence for all outcomes was either ‘low’ or ‘very low’. Limitations Included studies were mostly from high-income countries. Variable study outcomes and quality of evidence precluded meta-analysis. Conclusions Limited evidence favours integrated care for CSHCN using a dedicated key worker/care coordinator; however, heterogeneity in study outcomes and definitions of CSHCN limit the strength and utility of evidence obtained. Recommendations are made for improving integrated care practice, research and evaluation which are important for evidence-based health services for CSHCN. PROSPERO registration number CRD42020209320.